



To: Carter BloodCare Customers
From: Hospital Relations
Date: April 14, 2020
Re: Expanded Access Program- Convalescent Plasma

Background

As communicated on April 9, 2020, Carter BloodCare is working on recruiting donors who are interested in donating convalescent plasma.

While we work on determining eligibility and the collection of convalescent plasma for distribution through the national expanded access program (EAP), you can prepare by registering at <https://www.uscovidplasma.org>. Please follow the instructions on the EAP website for registration steps and guidelines associated with the program. The program will provide one unit of convalescent plasma per patient.

Impact to Client

Convalescent plasma collected and supplied via the EAP will be funded by the US Government Biomedical Advanced Research & Development Authority (BARDA) with no direct charge to your facility, but rather a payment made directly to Carter BloodCare.

Convalescent plasma products provided via the EAP pathway will be labeled with the following ISBT product codes— see attached frozen product code example labels. For added distinction from normal plasma products, a green tag with Convalescent Plasma will be attached to each unit.

E9754	Apheresis CONVALESCENT PLASMA ACD-A/XX/≤-18C 1st container COVID-19
E9755	Apheresis CONVALESCENT PLASMA ACD-A/XX/≤-18C 2nd container COVID-19
E9756	Apheresis CONVALESCENT PLASMA ACD-A/XX/≤-18C 3rd container COVID-19
E9757	Apheresis CONVALESCENT PLASMA ACD-A/XX/≤-18C 4th container COVID-19

Ordering Convalescent Plasma under EAP

- Ordering details will be forthcoming.

You will be notified when Carter BloodCare is able to fulfill orders under the expanded access program.

As a reminder, processes related to fulfillment of convalescent plasma orders through the emergency investigational new drug (eIND) pathway remain active and unchanged.

Please do not hesitate to contact us with any questions or concerns.